Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021

por Learned, Christine, Alsukait, Sara, Deverapalli, Sandhya, Elliott, Erika, Moody, Katherine, Sobell, Jeffrey, Konnikov, Nellie, Ortega, Melissa, Rosmarin, David
Publicado 2022

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis

por Ryan, Caitriona, Sobell, Jeffrey M., Leonardi, Craig L., Lynde, Charles W., Karunaratne, Mahinda, Valdecantos, Wendell C., Hendrickson, Barbara A.
Publicado 2018

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1

por Strober, Bruce E., Clay Cather, Jennifer, Cohen, David, Crowley, Jeffrey J., Gordon, Kenneth B., Gottlieb, Alice B., Kavanaugh, Arthur F., Korman, Neil J., Krueger, Gerald G., Leonardi, Craig L., Schwartzman, Sergio, Sobell, Jeffrey M., Solomon, Gary E., Young, Melodie
Publicado 2012

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

por Strober, Bruce E., Clay Cather, Jennifer, Cohen, David, Crowley, Jeffrey J., Gordon, Kenneth B., Gottlieb, Alice B., Kavanaugh, Arthur F., Korman, Neil J., Krueger, Gerald G., Leonardi, Craig L., Schwartzman, Sergio, Sobell, Jeffrey M., Solomon, Gary E., Young, Melodie
Publicado 2012